Results We identified 8,762 patients with evidence of a prescription or prescription fill for oral semaglutide during the first six weeks following FDA approval
Retatrutide and semaglutide are both effective for weight loss and managing type 2 diabetes, but retatrutide may work better for some people because it targets three hormones related to appetite control
Studies have shown that GLP-1 agonists can trigger effects in the brain, the heart, the liver, the pancreas, the stomach, and the musclesmeaning that they could have implications for conditions other than type 2 diabetes and obesity, such as heart disease, kidney disease, liver disease, and even neurological conditions such as Alzheimer's disease
Synthetic peptide with triple receptor agonist activity, C18 fatty acid modification for extended half-life
GLP1s, peptides, NAD, and regenerative techniques can be transformative when used thoughtfully